Metabolic syndrome, insulin resistance and oxidative stress: Adding insights to improve cardiovascular prevention

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1352-1354

  Amiri, Farhad ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NOTE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR;

EID: 67649755211     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d1f9e     Document Type: Note

References (29)

1. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program: Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13.
2. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26:1891-1900.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
4. Beaser RS, Levy P. Metabolic syndrome: a work in progress, but a useful construct. Circulation 2007; 115:1812-1818.
5. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation2007; 115:1806-1810.
6. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812-819.
7. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414.
8. Inchiostro S, Fadini GP, de Kreutzenberg SV, Citroni N, Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components? J Am Coll Cardiol 2007; 49:2465-2466.
9. Mancia G, Bombelli M, Facchetti R, Madotto F, CorraoG, Trevano FQ, et al.Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008; 26:1602-1611.
10. Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, Kuller LH. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29:123-130.
11. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640- 1649.
12. Kragelund C, Omland T. A farewell to body-mass index? Lancet 2005; 366:1589-1591.
13. Solbu MD, Kronborg J, Jenssen TG, Njolstad I, Lochen ML, Mathiesen EB, et al. Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis 2008. [Epub ahead of print]. doi: 10.1016/j.atherosclerosis.2008.11.002.
14. Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29:1689-1692.
15. GrundySM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin North Am 2004; 33:267-282.
16. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009; 89:27-71.
17. Touyz RM. Apocynin, NADPH oxidase, and vascular cells: a complex matter. Hypertension 2008; 51:172-174.
18. Schiffrin EL. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. Hypertension 2008; 51:31-32.
19. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164-2171.
20. Fortuno A, San JG, Moreno MU, Beloqui O, Diez J, Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006; 55:209-215.
21. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105:1429-1435.
22. Zalba G, Beloqui O, San JG, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25:1452-1457.
23. Zalba G, Fortuno A, Orbe J, San JG, Moreno MU, Belzunce M, et al.Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:587- 593.
24. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656-1662.
25. Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, et al.Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005; 179:43-49.
26. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 2004; 37:115-123.
27. Fortuño A, Bidegain J, San Jose' G, Robador PA, Landecho MF, Beloqui O, et al. Insulin resistance determines phagocytic NADPH oxidase overactivity in metabolic syndrome patients. J Hypertens 2009; 27:1420-1430.
28. Zalba G, Fortuno A, Orbe J, San JG, Moreno MU, Belzunce M, et al.Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:587-593.
29. Zalba G, Beloqui O, San JG, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25:1452-1457.